CDCP1 and cancer: Pre-clinical studies, involving the CD6-CD318 axis, and an anti-CD6 monoclonal antibody, suggest new strategies that could treat autoimmunity and cancer simultaneously, through distinct effects on subsets of lymphocytes CD6 blockade concurrently reduces Th1 and Th17 differentiation and increases T cell and NK cell cytotoxicity.